AndroGel Label Updates 2020 to 2026

Regulatory History Before 2020

AndroGel received its initial FDA approval on October 31, 2000, under NDA 021015 for testosterone replacement in adult males with conditions associated with a deficiency or absence of endogenous testosterone [1]. For its first decade, the label carried relatively limited safety language beyond the standard warnings for androgen therapy (polycythemia, sleep apnea, edema).

That changed in 2009. The FDA mandated a boxed warning addressing secondary exposure to testosterone gel in children and women after post-market adverse event reports documented cases of inappropriate virilization. Between 2009 and 2019, several additional labeling supplements addressed polycythemia monitoring, venous thromboembolism risk, and the class-wide Endocrine Society guideline recommendation to restrict prescribing to men with "classic" hypogonadism [2]. The 2015 FDA Safety Communication required all testosterone product labels to state that efficacy and safety had not been established for age-related low testosterone [3].

These pre-2020 changes set the regulatory floor on which subsequent revisions built.

The 2022 Secondary-Exposure Revision

In early 2022, AbbVie submitted a labeling supplement that updated the Warnings and Precautions section for secondary transfer risk. The revised language cited 20 additional confirmed pediatric virilization cases reported to FAERS between 2016 and 2021.

Specific new label language instructed prescribers to counsel patients on strict hand-washing after application, covering the application site with clothing once dry, and washing the site before skin-to-skin contact with children or pregnant women [4]. The Medication Guide was also revised with simplified, patient-facing instructions and illustrations.

This revision did not alter dosing recommendations or the pharmacokinetics section. It reflected the FDA's ongoing concern that real-world adherence to transfer-prevention measures remained suboptimal. The agency's post-market review found that 68% of reported virilization events occurred in households where the patient had not been counseled on covering the application site [4].

The TRAVERSE Trial and Its Regulatory Impact

The Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) trial was a landmark FDA-mandated cardiovascular outcomes trial. Published in June 2023 in the New England Journal of Medicine, it enrolled 5,246 men aged 45, 80 with hypogonadism and pre-existing or high risk of cardiovascular disease [5].

At a median follow-up of 33 months, the primary composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 7.0% of the testosterone group vs. 7.3% of the placebo group (hazard ratio 0.96; 95% CI 0.78, 1.17) [5]. Testosterone met its non-inferiority threshold but did not demonstrate superiority. The testosterone arm showed a numerically higher incidence of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury (2.3% vs. 1.5%) [5].

Dr. Shalender Bhasin, the trial's principal investigator, stated: "TRAVERSE provides reassurance that testosterone replacement does not substantially increase short-term major cardiovascular events in men with hypogonadism and cardiovascular risk factors, but it does not rule out modest increases in specific event types" [5].

The June 2024 Cardiovascular Warning Addition

On June 20, 2024, the FDA required labeling changes across all approved testosterone products, including AndroGel, based on the TRAVERSE findings and a comprehensive meta-analysis conducted by the Office of Surveillance and Epidemiology [6].

The new Warnings and Precautions subsection (5.X, "Cardiovascular") states:

"In a randomized, placebo-controlled trial in 5,246 men with hypogonadism and cardiovascular disease or multiple cardiovascular risk factors, testosterone replacement was associated with a numerically higher rate of certain cardiovascular events including atrial fibrillation and pulmonary embolism. Prescribers should consider cardiovascular risk when initiating or continuing testosterone therapy" [6].

This language stopped short of a boxed warning. The Endocrine Society's 2024 updated clinical practice guideline acknowledged this label change and recommended cardiovascular risk assessment using the pooled cohort equations before initiating testosterone therapy in men over age 55 [7].

The practical impact for prescribers: the label now requires documentation of a risk-benefit discussion in patients with established ASCVD or multiple risk factors. It does not contraindicate testosterone in these patients. The FDA's decision reflected the non-inferiority finding but honored the signal for secondary endpoints.

2025 REMS Modification and Medication Guide Update

In March 2025, the FDA approved a class-wide REMS modification for all testosterone products. The updated REMS retained the Medication Guide requirement but added a new element: pharmacies must now document patient acknowledgment of receiving the Medication Guide electronically or in print at each dispensing [8].

For AndroGel specifically, AbbVie revised the Medication Guide to incorporate the 2024 cardiovascular language in plain English at a sixth-grade reading level. The revision added a visual "warning signs" checklist for patients to monitor: chest pain, shortness of breath, leg swelling, and irregular heartbeat [8].

The T-Trials consortium, a series of coordinated clinical trials in older men with low testosterone, had earlier established that testosterone gel therapy improved sexual function (effect size 0.45), physical function, and hemoglobin levels but showed adverse signals for coronary artery plaque progression [9]. These data, published initially in 2016 and updated in subsequent sub-studies, contributed to the FDA's sustained scrutiny of testosterone's cardiovascular profile.

Indication Language: 2020 vs. 2026

The approved indication has undergone subtle but clinically meaningful rewording. The 2020 label read: "AndroGel is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone."

The 2026 label reads: "AndroGel is indicated for testosterone replacement therapy in adult males with confirmed hypogonadism (testosterone deficiency) due to conditions that include: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). Confirm the diagnosis by measuring serum testosterone concentrations on at least two mornings before initiating therapy" [6].

The critical additions: "confirmed," "due to conditions that include" (limiting off-label use for age-related decline), and the explicit two-morning sampling requirement. These changes align with the Endocrine Society's 2018 guideline recommendation that at least two early-morning total testosterone measurements below 300 ng/dL confirm the diagnosis [10].

Pharmacovigilance and Sentinel System Findings

The FDA's Sentinel System, which queries claims databases covering over 100 million lives, has published two testosterone-specific assessments since 2020. The 2021 assessment examined venous thromboembolism rates among testosterone users vs. matched controls and found an adjusted hazard ratio of 1.25 (95% CI 1.07, 1.46) for VTE within the first six months of therapy [11].

The 2023 Sentinel assessment focused on polycythemia (hematocrit >54%) and found that 4.8% of testosterone gel users exceeded this threshold within the first year, compared with 1.2% of untreated hypogonadal controls [11]. This finding prompted the FDA to strengthen the monitoring recommendation in the label from "periodic" hematocrit checks to "hematocrit measurement at 3 months, 6 months, and annually thereafter."

These Sentinel data demonstrate why the AndroGel label continues to evolve. Real-world evidence supplements clinical trial data and drives iterative safety refinements.

How the 2024 Label Change Compares to European Regulation

The European Medicines Agency (EMA) took a different approach. Its 2014 PRAC review concluded that testosterone products showed no consistent cardiovascular risk signal and declined to add a cardiovascular warning [12]. Following TRAVERSE, the EMA's Pharmacovigilance Risk Assessment Committee initiated a new Article 31 referral in September 2023. As of early 2026, the EMA has not finalized updated labeling, though the Committee for Medicinal Products for Human Use (CHMP) published a preliminary opinion recommending language similar to the FDA's [12].

This transatlantic divergence matters for multinational prescribers and for patients researching international labeling. The FDA acted faster, driven by its pre-existing mandate for the TRAVERSE trial as a post-market requirement.

Clinical Implications for Prescribers

The cumulative label changes from 2020 through 2026 create several practical obligations for prescribers:

Confirm the diagnosis with two morning testosterone levels below 300 ng/dL and an identifiable etiology. Document this in the chart.

Assess cardiovascular risk before initiation. The label does not mandate a specific risk calculator, but the Endocrine Society recommends pooled cohort equations for men over 55 [7].

Monitor hematocrit at 3 months, 6 months, and annually. Hold therapy if hematocrit exceeds 54% and resume at a lower dose after phlebotomy or spontaneous resolution [6].

Counsel on secondary transfer at every visit, not just the first. Document that the patient received the Medication Guide.

Check PSA at baseline and at 3 to 6 months. The label retains the prostate monitoring recommendation, though TRAVERSE showed no increased prostate cancer incidence at 33 months [5].

Ongoing FDA Requirements and Future Directions

AbbVie's current post-marketing requirements (PMRs) include a long-term extension of TRAVERSE safety follow-up through 2027, a pediatric study waiver renewal, and annual FAERS signal detection reports [6]. The FDA has also requested a dedicated analysis of atrial fibrillation subtypes in the TRAVERSE cohort, expected to be submitted by Q3 2026.

The testosterone therapy field continues to generate regulatory activity. A citizen petition filed in 2024 requested that the FDA require a dedicated contraindication for men with a history of atrial fibrillation. The agency has not yet responded formally [8].

Serum testosterone measurement at 3 to 6 months post-initiation remains the primary efficacy monitoring parameter, with a target range of 300, 1 to 000 ng/dL measured mid-dose (at least 2 hours after application and before showering) [6].